HCG reported a total income of Rs.326.58 crores during the period ended June 30, 2021, as compared to Rs 196.18 crores during the corresponding period last year. The total income for the period ended March 31, 2021, stood at Rs 302.45 crores.

The company has posted a net profit / (loss) of Rs. (9.57) crores for the period ended June 30, 2021, as against a net profit/loss of Rs (39.75) crores for the corresponding period last year. For the quarter ended March 31, 2021, the company reported a net profit/(loss) of Rs (102.17) crores.

The company has reported EPS of Rs.(0.76) for the period ended June 30, 2021, compared to Rs (4.48) for the corresponding period last year. For the period ended March 31, 2021, the EPS stood at Rs (8.14).

Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises Ltd. said, “We are pleased to report Q1 FY22 results having emerged with a strong performance on all counts while weathering the 2nd wave of the pandemic. The quarter started with rising cases, travel restrictions and lockdowns, which threatened to disrupt operations substantially, but we are proud to say that we were not only able to maintain continuity of treatment for cancer patients through the usage of technology systems but also ensured the highest quality of care’’

He further added, ``HCG has institutionalised tumour boards, research and academics across its centres and continues to bring globally comparable outcomes to every patient, along with creating last-mile access and better quality of life. With growing oncology disease burden, the inherent strengths and future outlook of the HCG model are best suited to provide superior outcomes for patients while sustainably achieving the desired objectives of all stakeholders, over the coming years.”

Mr. Raj Gore, CEO HealthCare Global Enterprises Ltd., added, “We are satisfied with the performance in Q1- FY22, which was also during one of the most testing times we may have seen in our lives. The fact that we have not only emerged successfully but also created new performance benchmarks as an organization, is a testament to the clinical expertise and overall value proposition that we offer. HCG’s large patient catchment of over 640mn population in states of presence and market position across these regions is a great platform helping us in redefining the quality of care and outcomes at scale, thus driving clinical and geographic leadership. We continue to focus on disciplined capital allocation as we implement strategic initiatives across business development and digital health while carrying strong momentum from Q1 into the current quarter. We are excited about the next few years as being truly transformative for HCG, to continue our dominant leadership in oncology, while delivering a strong return on capital and meeting our responsibilities towards all stakeholders.”